We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Omicia Acquires Spiral Genetics

Omicia Acquires Spiral Genetics content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Omicia has announced that it has acquired Seattle-based Spiral Genetics. Spiral’s advanced tools add multiple variant detection capabilities for next-generation sequencing (NGS) to Omicia’s software platform. 

Spiral’s  graph-based technology enables accurate detection of structural variants and provides population-scale data-mining capabilities for clinical laboratories, life science companies and country sequencing programs. Also included in the acquisition are Spiral’s population-specific reference genome and lossless data compression technologies. As a result, Omicia and its customers will have new opportunities to develop novel diagnostics and efficiently manage long-term genomic data storage. 

“We’re excited to combine our team and technology with Omicia. Access to Omicia’s diverse customer base, global market position and market-leading platform will help us define the future of healthcare,” said Adina Mangubat, CEO of Spiral Genetics. “Omicia and Spiral have come together to create the most advanced, end-to-end bioinformatics solution in healthcare.” 

Omicia now offers a secure, powerful range of NGS analysis capabilities to support high- throughput panels, exomes and whole genomes for identification of hereditary diseases and somatic cancer, delivering clinical reports straight into electronic medical record (EMR) workflows. Omicia’s technology has been used by more than 1,000 research institutions and clinical labs, including population sequencing initiatives (e.g. Genomics England), health systems and hospitals (e.g. University of Pittsburgh Medical Center and Rady Children’s Hospital - San Diego) and national reference laboratories (e.g. LabCorp). 

“The strategic integration of Spiral’s technologies effectively cements Omicia’s leadership position in precision medicine. By removing the need to access multiple software platforms, we improves quality, accuracy and turnaround time, removing major roadblocks to clinical adoption,” said Matt Tindall, CEO of Omicia. “Spiral brings a world-class team of commercial leaders, computer scientists and computational biologists with deep expertise in large-scale genome analysis and algorithm development, as well as proven technology and customers.” 

This article has been republished from materials provided by Omicia. Note: material may have been edited for length and content. For further information, please contact the cited source.